<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735617</url>
  </required_header>
  <id_info>
    <org_study_id>DIUR-003</org_study_id>
    <nct_id>NCT01735617</nct_id>
  </id_info>
  <brief_title>Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH</brief_title>
  <official_title>A Phase 2 Pilot Study to Characterize and Examine the Pharmacokinetics and Disease Bio-marker Response of Chronocort® in Adults With Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diurnal Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Diurnal Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather safety and effectiveness information about a new
      formulation of Hydrocortisone (Chronocort®) used to treat patients with a disease called
      congenital adrenal hyperplasia (CAH). Hydrocortisone is the man-made version of the hormone
      cortisol, which is released in the body following a regular daily pattern. The objective of
      the study is to measure the levels of hydrocortisone that are absorbed into the bloodstream
      once Chronocort® is taken and what affects it has on other hormones in the body. Since
      Chronocort® is anticipated to mimic the same release pattern of cortisol in the body, it is
      hoped that patients with CAH will be treated more effectively to manage their disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2 pilot study to characterize and examine the pharmacokinetics and
      efficacy profile of Chronocort® in adults with congenital adrenal hyperplasia (CAH). It is
      designed as a two-part, single cohort, open label, multiple dose Phase 2 pilot study to:
      (Part A) characterize and examine the pharmacokinetics (PK) and disease bio-marker behavior
      following short-term dosing with Chronocort®; and to (Part B) examine the disease control
      after six months dose titration with Chronocort® in adults with CAH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</measure>
    <time_frame>24 hours</time_frame>
    <description>The maximum plasma concentration (Cmax) of chronocort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</measure>
    <time_frame>24 hours (at 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)</time_frame>
    <description>Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to maximum plasma concentration (tmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With 17-OHP and Androstenedione Levels at 0700h Within Proposed Optimal Ranges Whilst on Chronocort and Whilst on Standard Therapy (at Baseline)</measure>
    <time_frame>Specific time point (0700hrs)</time_frame>
    <description>Proposed optimal ranges of 17-OHP: 300-1200ng/dl Proposed optimal ranges of androstenedione: 40-150ng.dl for males and 30-200ng/dl for females</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17-OHP Levels at 0700h, 1700h and 2300h</measure>
    <time_frame>Specified time points (0700h, 1700h and 2300h)</time_frame>
    <description>17-OHP levels at 0700h, 1700h and 2300h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione Levels at 0700h, 1700h and 2300h</measure>
    <time_frame>Specified time points (0700h, 1700h and 2300h)</time_frame>
    <description>Androstenedione levels at 0700h, 1700h and 2300h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTH Levels at 0700h, 1700h and 2300h</measure>
    <time_frame>Specified time points (0700h, 1700h and 2300h)</time_frame>
    <description>ACTH levels at 0700h, 1700h and 2300h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Values (Nmol*h/L) for Androstenedione</measure>
    <time_frame>Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)</time_frame>
    <description>AUC values (nmol*h/L) for Androstenedione for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Values (Nmol*h/L) for 17-OHP</measure>
    <time_frame>Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)</time_frame>
    <description>AUC values (nmol*h/L) for 17-OHP for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Values (Pmol*h/L) for ACTH</measure>
    <time_frame>Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)</time_frame>
    <description>AUC values (pmol*h/L) for ACTH for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Endocrine Disease</condition>
  <condition>Adrenal Insufficiency</condition>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone Modified Release Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Modified Release Capsules</intervention_name>
    <description>Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
    <arm_group_label>Hydrocortisone Modified Release Capsules</arm_group_label>
    <other_name>Chronocort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and genetic
             testing currently treated with hydrocortisone, prednisone, prednisolone or
             dexamethasone on a stable dosage for a minimum of 3 months.

          2. Male or female patients aged 18 and above.

          3. Provision of signed written informed consent.

          4. Good general health.

          5. Females of childbearing potential must have a negative pregnancy test initially and at
             all visits. Females who are engaging in sexual intercourse must be using a medically
             acceptable method of contraception (as defined in the protocol, section 10.5).

          6. Plasma renin activity must be within the clinically acceptable range at screening
             (less than 1.5 times upper normal range).

        Exclusion Criteria:

          1. Co-morbid condition requiring daily administration of a medication that induces
             hepatic enzymes or interferes with the metabolism of glucocorticoids.

          2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the
             normal range or elevated liver function tests (ALT or AST) &gt; 2 times the upper limits
             of normal.

          3. Females who are pregnant or lactating.

          4. Women taking an estrogen-containing oral contraceptive pill and who have taken it
             within 6 weeks of recruitment.

          5. Patients taking spironolactone.

          6. Patients on inhaled or oral steroids apart from treatment for CAH.

          7. Patients with any other significant medical or psychiatric conditions that in the
             opinion of the Investigator would preclude participation in the trial.

          8. Participation in another clinical trial of an investigational or licensed drug or
             device within the 3 months prior to inclusion in this study.

          9. Patients with history of bilateral adrenalectomy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah P Merke, BS, MS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>November 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <results_first_submitted>June 25, 2015</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>congenital adrenal hyperplasia</keyword>
  <keyword>glucocorticoids</keyword>
  <keyword>cortisol</keyword>
  <keyword>adrenal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydrocortisone Modified Release Capsules</title>
          <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Hydrocortisone Modified Release Capsules</title>
          <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="12.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</title>
        <description>The maximum plasma concentration (Cmax) of chronocort</description>
        <time_frame>24 hours</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Chronocort</title>
            <description>Chronocort Modified Release Capsules 10 mg twice-daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</title>
          <description>The maximum plasma concentration (Cmax) of chronocort</description>
          <population>All treated subjects</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="601.213" spread="114.5987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The pharmacokinetic profile was characterised by an overnight rise in cortisol levels reaching a maximal concentration approximately 8 hours post dosing.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric means</param_type>
            <param_value>563.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>162.51</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</title>
        <description>Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)</description>
        <time_frame>24 hours (at 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Chroncort</title>
            <description>Chronocort Modified Release Capsules 10mg twice-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profile (AUC0-24) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</title>
          <description>Area under the curve (AUC) from 0 to 24 hours (sampling occurs at the following timepoints: 2300, 0100, 0300, 0500, 0600, 0700, 0800, 0900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1900, 2100, 2300hrs)</description>
          <population>All treated subjects</population>
          <units>h*nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5027.641" spread="1247.8425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</title>
        <description>Time to maximum plasma concentration (tmax)</description>
        <time_frame>24 hours</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Chronocort</title>
            <description>Chronocort Modified Release Capsules 10mg twice-daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profile (Tmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia</title>
          <description>Time to maximum plasma concentration (tmax)</description>
          <population>All treated subjects</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With 17-OHP and Androstenedione Levels at 0700h Within Proposed Optimal Ranges Whilst on Chronocort and Whilst on Standard Therapy (at Baseline)</title>
        <description>Proposed optimal ranges of 17-OHP: 300-1200ng/dl Proposed optimal ranges of androstenedione: 40-150ng.dl for males and 30-200ng/dl for females</description>
        <time_frame>Specific time point (0700hrs)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With 17-OHP and Androstenedione Levels at 0700h Within Proposed Optimal Ranges Whilst on Chronocort and Whilst on Standard Therapy (at Baseline)</title>
          <description>Proposed optimal ranges of 17-OHP: 300-1200ng/dl Proposed optimal ranges of androstenedione: 40-150ng.dl for males and 30-200ng/dl for females</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>17-OHP (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP (final visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione (final visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>17-OHP Levels at 0700h, 1700h and 2300h</title>
        <description>17-OHP levels at 0700h, 1700h and 2300h</description>
        <time_frame>Specified time points (0700h, 1700h and 2300h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>17-OHP Levels at 0700h, 1700h and 2300h</title>
          <description>17-OHP levels at 0700h, 1700h and 2300h</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>17-OHP: Part A, Days 1-2 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.97" spread="91.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 1-2 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.99" spread="104.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 1-2 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.35" spread="93.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.72" spread="8.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.55" spread="66.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.27" spread="55.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.86" spread="54.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.17" spread="20.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.65" spread="51.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.87" spread="49.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.81" spread="20.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.95" spread="28.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.67" spread="19.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.70" spread="69.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.19" spread="46.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Androstenedione Levels at 0700h, 1700h and 2300h</title>
        <description>Androstenedione levels at 0700h, 1700h and 2300h</description>
        <time_frame>Specified time points (0700h, 1700h and 2300h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>Androstenedione Levels at 0700h, 1700h and 2300h</title>
          <description>Androstenedione levels at 0700h, 1700h and 2300h</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Androstenedione: Part A, Days 1-2 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="8.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 1-2 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.54" spread="7.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 1-2 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" spread="9.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="2.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="8.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="8.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="6.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="3.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="3.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" spread="3.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="2.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" spread="3.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="1.973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="4.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="2.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACTH Levels at 0700h, 1700h and 2300h</title>
        <description>ACTH levels at 0700h, 1700h and 2300h</description>
        <time_frame>Specified time points (0700h, 1700h and 2300h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>ACTH Levels at 0700h, 1700h and 2300h</title>
          <description>ACTH levels at 0700h, 1700h and 2300h</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACTH: Part A, Days 1-2 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.06" spread="29.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 1-2 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.93" spread="30.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 1-2 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="9.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="9.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="7.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="7.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" spread="12.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.57" spread="6.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="14.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.66" spread="12.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="6.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="7.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 (0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.18" spread="29.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 (1700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="22.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 (2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.44" spread="17.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Values (Nmol*h/L) for Androstenedione</title>
        <description>AUC values (nmol*h/L) for Androstenedione for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
        <time_frame>Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Values (Nmol*h/L) for Androstenedione</title>
          <description>AUC values (nmol*h/L) for Androstenedione for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Androstenedione: Part A, Days 1-2 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.19" spread="171.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 1-2 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.42" spread="34.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 1-2 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.33" spread="76.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 1-2 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.44" spread="65.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.37" spread="128.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.02" spread="40.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.01" spread="31.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part A, Days 4-5 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.91" spread="58.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.58" spread="86.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.12" spread="43.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.07" spread="22.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 2 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.39" spread="23.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.46" spread="65.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.25" spread="26.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.92" spread="16.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 3 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.30" spread="26.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.27" spread="70.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.09" spread="23.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.03" spread="20.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Androstenedione: Part B, Visit 4 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.13" spread="28.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Values (Nmol*h/L) for 17-OHP</title>
        <description>AUC values (nmol*h/L) for 17-OHP for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
        <time_frame>Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Values (Nmol*h/L) for 17-OHP</title>
          <description>AUC values (nmol*h/L) for 17-OHP for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
          <units>nmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>17-OHP: Part A, Days 1-2 AUC 2300-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1407.83" spread="1829.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 1-2 AUC 2300-0700h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.99" spread="339.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 1-2 AUC 0700-1500h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="607.74" spread="805.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 1-2 AUC 1500-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556.11" spread="769.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 AUC 2300-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="446.90" spread="817.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 AUC 2300-0700h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.83" spread="268.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 AUC 0700-1500h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.53" spread="147.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part A, Days 4-5 AUC 1500-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.73" spread="425.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 AUC 2300-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.65" spread="587.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 AUC 2300-0700h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.01" spread="337.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 AUC 0700-1500h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.41" spread="91.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 2 AUC 1500-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.24" spread="215.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 AUC 2300-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432.02" spread="393.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 AUC 2300-0700h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.63" spread="144.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 AUC 0700-1500h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.21" spread="147.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 3 AUC 1500-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.18" spread="182.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 AUC 2300-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.54" spread="678.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 AUC 2300-0700h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.33" spread="148.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 AUC 0700-1500h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.32" spread="172.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-OHP: Part B, Visit 4 AUC 1500-2300h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.89" spread="364.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC Values (Pmol*h/L) for ACTH</title>
        <description>AUC values (pmol*h/L) for ACTH for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
        <time_frame>Specific time points (2300-2300h, 2300-0700h, 0700-1500h and 1500-2300h)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocortisone Modified Release Capsules</title>
            <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Values (Pmol*h/L) for ACTH</title>
          <description>AUC values (pmol*h/L) for ACTH for the following reporting periods: 24 hours (2300-2300h), 2300-0700h, 0700-1500h and 1500-2300h</description>
          <units>pmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACTH: Part A, Days 1-2 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356.25" spread="415.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 1-2 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.72" spread="70.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 1-2 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.18" spread="206.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 1-2 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.35" spread="169.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.00" spread="121.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.22" spread="62.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.29" spread="19.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part A, Days 4-5 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.13" spread="57.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.45" spread="118.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.09" spread="46.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.14" spread="48.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 2 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.22" spread="49.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.10" spread="172.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.02" spread="57.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.46" spread="64.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 3 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.63" spread="70.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 AUC (2300-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.30" spread="420.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 AUC (2300-0700h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.80" spread="107.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 AUC (0700-1500h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.58" spread="329.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTH: Part B, Visit 4 AUC (1500-2300h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.92" spread="120.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydrocortisone Modified Release Capsules</title>
          <description>Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
Hydrocortisone Modified Release Capsules: Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite decrease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Appetite increase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CEO</name_or_title>
      <organization>Diurnal Ltd.</organization>
      <phone>+44 (0) 871 716 8848</phone>
      <email>info@diurnal.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

